InsidersTradesSigma
HH
HARROW HEALTH, INC. Stock: price and insider trades · United States · SEC (Form 4)
Track the HARROW HEALTH, INC. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, HARROW HEALTH, INC. has published 17 public disclosures. Market capitalisation: €1.2bn. The latest transaction was disclosed on 20 September 2023 (Acquisition). Among the most active insiders: BAUM MARK L. Every trade is openly available.
17
Insider Decl.
0
Thresholds
€5m
9 ops.
Buy Volume
€513,553
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate HARROW HEALTH, INC. Strong Buy (bullish), based on 8 analysts. Average price target: US$67.75.
52Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 19,889 of 26,211 companies
33.8
score / 100
Value28
Quality40
FCF yld·
Earn yld-0.4%
EV/EBITDA·
ROE-35%
Gross mgn75%
Net mgn-1.9%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 20 September 2023
Declarations17 total
14,017 shares@ US$14.65123.8% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-23-033247:0
Ideal exit: 15 Jun 2024 (T+270)
20,000 shares@ US$16.9249.7% of flowCommon StockSEC:0001493152-23-028830:0
Ideal exit: 10 May 2024 (T+270)
5,800 shares@ US$17.054.2% of flowCommon StockSEC:0001493152-23-028832:0
Ideal exit: 10 May 2024 (T+270)
762,300 sharesCommon StockSEC:0001493152-23-025150:0
277,200 sharesCommon StockSEC:0001493152-23-025148:0
346,500 sharesCommon StockSEC:0001493152-23-025146:0
180,000 shares@ US$8.9968.9% of flowCommon StockSEC:0001493152-23-010886:0
90,000 shares@ US$6.0093.9% of flowCommon StockSEC:0001493152-23-010882:0
88,000 sharesCommon StockSEC:0001493152-23-000190:0
23,000 sharesCommon StockSEC:0001493152-23-000191:0
25,000 shares@ US$13.3914.7% of flowCommon StockSEC:0001493152-22-036396:0
Ideal exit: 18 Sept 2023 (T+270)
25,000 shares@ US$13.3750.3% of flowCommon StockSEC:0001493152-22-036394:0
Ideal exit: 17 Sept 2023 (T+270)
2,500 shares@ US$13.546.1% of flowCommon StockSEC:0001493152-22-036395:0
Ideal exit: 18 Sept 2023 (T+270)
1,860 shares@ US$13.42100.0% of flowCommon StockSEC:0001493152-22-036393:0
Ideal exit: 18 Sept 2023 (T+270)
415,000 shares@ US$10.5280.8% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-22-035435:0
Ideal exit: 10 Sept 2023 (T+270)
40,000 shares@ US$12.6278.3% of flowCommon StockSEC:0001493152-22-027463:0
10,000 shares@ US$9.77482.0% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-22-027192:0
Ideal exit: 25 Jun 2023 (T+270)
17 of 17 declarations
About HARROW HEALTH, INC.
Harrow, Inc. (NASDAQ: HROW) is a United States-based ophthalmic healthcare company focused on eye disease management. Headquartered in Nashville, Tennessee, Harrow has evolved from its former identity as Imprimis Pharmaceuticals into a more specialized eye-care platform with a sharper strategic focus. That repositioning has helped the company build a business model centered on serving ophthalmologists, surgeons, and patients with chronic or procedure-related ocular conditions. Harrow’s core business is built around two complementary pillars: branded ophthalmic pharmaceuticals and compounded/specialty pharmacy products through ImprimisRx, its ophthalmic compounding platform. The company offers a portfolio spanning treatments used in cataract surgery, inflammation, dry eye, and retinal disease management. In addition to its commercially marketed products, Harrow has pursued selective licensing and portfolio expansion strategies to broaden its ophthalmology offering and improve access to therapies. More recently, the company has also added biosimilar ophthalmology rights and other specialty assets intended to strengthen its long-term commercial mix. From a competitive standpoint, Harrow occupies a differentiated niche in the U.S. eye-care market. Its hybrid model — combining compounded medicines, branded products, and commercialization rights — is uncommon and gives the company exposure to multiple layers of the ophthalmology value chain. This structure can support customer retention and commercial flexibility, while also making Harrow more specialized than diversified large-cap pharma peers. The company’s presence is primarily in the United States, where it focuses on building a national commercial footprint around ophthalmology practices, specialty pharmacies, and care providers. Recent developments underscore Harrow’s growth-oriented profile. In 2025, management reaffirmed a full-year revenue outlook in the $270–280 million range and highlighted continued execution across commercial and development programs. The company also reported formulary coverage gains and additional specialty pharmacy partnerships. Another notable strategic move came in 2025, when Harrow secured exclusive U.S. commercial rights to Samsung Bioepis ophthalmology biosimilars, including products referencing Lucentis and Eylea, which could deepen its position in retinal medicine. For investors, Harrow should be viewed as a focused ophthalmology platform listed on the U.S. NASDAQ market, with a business model tied to specialty healthcare demand, product execution, reimbursement dynamics, and ongoing pipeline/portfolio expansion.
